Stockreport

TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

TScan Therapeutics, Inc.  (TCRX) 
PDF Reached agreement with FDA on pivotal study design for TSC-101 following productive end of Phase 1 meeting Data from ALLOHA™ Phase 1 heme trial to be presented at the 6 [Read more]